President Trump may like to use the bully pulpit to call on drug makers to lower their prices, but most Americans don’t believe his tough talk will make much of a difference.

To be specific, 55 percent of Americans say his strategy of publicly calling on drug companies to lower their costs will not be too effective or at all effective, according to a poll by the Kaiser Family Foundation. By comparison, 42 percent say this approach will be very or somewhat effective.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Methinks our venerable scribe could have economized on ink in the title to this post – “Most Americans don’t believe Trump’s tough talk” would have been quite sufficient.
    It might even have generated more clicks from the non-pharma crowd while still being …. accurate.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy